Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net earnings	$ 96,182	$ 79,927
Adjustments to reconcile net earnings to net cash provided by operating activities:
Share-based compensation expense	13,440	11,223
Depreciation and amortization	12,621	5,029
Amortization of premium/discount on marketable securities	(3,217)	(3,058)
Amortization of deferred financing costs and debt discount	12,351	11,701
Realized gains from sales of marketable securities	(3,636)	(131)
Change in fair value of contingent consideration	200	0
Noncash interest expense	4,515	4,331
Noncash royalty revenue	(6,320)	(5,028)
Noncash operating lease cost	2,599	2,600
Deferred income tax benefit	(280)	(1,689)
Changes in operating assets and liabilities:
Accounts receivable	(26,840)	16,344
Inventories	(5,437)	155
Prepaid expenses and other current assets	(9,318)	(4,236)
Other noncurrent assets	(2,416)	(141)
Accounts payable	(1,527)	(334)
Accrued product returns and rebates	21,166	(9,013)
Accrued expenses and other current liabilities	8,410	1,120
Income taxes payable	(2,538)	(7,559)
Other liabilities	(3,489)	(1,903)
Net cash provided by operating activities	106,466	99,338
Cash flows from investing activities
Acquisition of USWM, net of cash acquired	(297,200)	0
Investment in Navitor Pharmaceuticals, Inc.	(15,000)	0
Purchases of marketable securities	(87,890)	(361,121)
Sales and maturities of marketable securities	319,421	184,467
Purchases of property and equipment	(3,234)	(707)
Deferred legal fees	(141)	(1)
Net cash used in investing activities	(84,044)	(177,362)
Cash flows from financing activities
Payments on finance lease liability	(1,056)	0
Proceeds from issuance of common stock	1,546	2,665
Net cash provided by financing activities	490	2,665
Net change in cash and cash equivalents	22,912	(75,359)
Cash and cash equivalents at beginning of year	181,381	192,248
Cash and cash equivalents at end of period	204,293	116,889
Supplemental cash flow information
Cash paid for interest on convertible notes	2,516	2,516
Cash paid for income taxes	42,284	35,933
Noncash investing and financing activities
Contingent consideration liability accrued in USWM Acquisition	115,900	0
Deferred legal fees and fixed assets included in accounts payable and accrued expenses	352	495
Property and equipment additions from utilization of tenant improvement allowance	0	387
Lease assets and tenant receivable obtained for new leases	$ 25,225	$ 31,856